Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa-3)

Trial Overview

Am I Eligible?

Participating US Centers

John Theurer Cancer Center
Hackensack Meridian Health

This center is currently accepting patients.

Hackensack, NJ


Winship Cancer Institute
Emory University

This center has not yet started accepting patients.

Atlanta, GA


Siteman Cancer Center
Washington University Medical Campus

This center is currently accepting patients.

St. Louis, MO


Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center

This center has not yet started accepting patients.

New York, NY


Sarah Cannon
TriStar Centennial Medical Center

This center is currently accepting patients.

Nashville, TN


University of Colorado Cancer Center
Anschutz Cancer Pavilion

This center has not yet started accepting patients.

Aurora, CO


University of Texas Southwest Medical Center (Simmons Cancer Center)

This center has not yet started accepting patients.

Dallas, TX


University of Pittsburgh Medical Center (UPMC)

This center has not yet started accepting patients.

Pittsburgh, PA

ACCEPTING

This trial is currently open and accepting patients.



Additional Information
Trial Phase

Phase 3

Trial Enrollment

381 sparks required

Trial Sponsors
  • Celgene Corporation
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;